Your browser doesn't support javascript.
loading
Noninvasive Molecular Subtyping of Pediatric Low-Grade Glioma with Self-Supervised Transfer Learning.
Tak, Divyanshu; Ye, Zezhong; Zapaischykova, Anna; Zha, Yining; Boyd, Aidan; Vajapeyam, Sridhar; Chopra, Rishi; Hayat, Hasaan; Prabhu, Sanjay P; Liu, Kevin X; Elhalawani, Hesham; Nabavizadeh, Ali; Familiar, Ariana; Resnick, Adam C; Mueller, Sabine; Aerts, Hugo J W L; Bandopadhayay, Pratiti; Ligon, Keith L; Haas-Kogan, Daphne A; Poussaint, Tina Y; Kann, Benjamin H.
Afiliação
  • Tak D; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Ye Z; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Zapaischykova A; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Zha Y; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Boyd A; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Vajapeyam S; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Chopra R; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Hayat H; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Prabhu SP; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Liu KX; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Elhalawani H; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Nabavizadeh A; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Familiar A; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Resnick AC; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Mueller S; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Aerts HJWL; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Bandopadhayay P; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Ligon KL; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Haas-Kogan DA; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Poussaint TY; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
  • Kann BH; From the Artificial Intelligence in Medicine Program, Mass General Brigham, Harvard Medical School, Boston, Mass (D.T., Z.Y., A.Z., Y.Z., A.B., R.C., H.H., H.J.W.L.A., B.H.K.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston Children's Hospital, H
Radiol Artif Intell ; 6(3): e230333, 2024 May.
Article em En | MEDLINE | ID: mdl-38446044
ABSTRACT
Purpose To develop and externally test a scan-to-prediction deep learning pipeline for noninvasive, MRI-based BRAF mutational status classification for pediatric low-grade glioma. Materials and Methods This retrospective study included two pediatric low-grade glioma datasets with linked genomic and diagnostic T2-weighted MRI data of patients Dana-Farber/Boston Children's Hospital (development dataset, n = 214 [113 (52.8%) male; 104 (48.6%) BRAF wild type, 60 (28.0%) BRAF fusion, and 50 (23.4%) BRAF V600E]) and the Children's Brain Tumor Network (external testing, n = 112 [55 (49.1%) male; 35 (31.2%) BRAF wild type, 60 (53.6%) BRAF fusion, and 17 (15.2%) BRAF V600E]). A deep learning pipeline was developed to classify BRAF mutational status (BRAF wild type vs BRAF fusion vs BRAF V600E) via a two-stage process (a) three-dimensional tumor segmentation and extraction of axial tumor images and (b) section-wise, deep learning-based classification of mutational status. Knowledge-transfer and self-supervised approaches were investigated to prevent model overfitting, with a primary end point of the area under the receiver operating characteristic curve (AUC). To enhance model interpretability, a novel metric, center of mass distance, was developed to quantify the model attention around the tumor. Results A combination of transfer learning from a pretrained medical imaging-specific network and self-supervised label cross-training (TransferX) coupled with consensus logic yielded the highest classification performance with an AUC of 0.82 (95% CI 0.72, 0.91), 0.87 (95% CI 0.61, 0.97), and 0.85 (95% CI 0.66, 0.95) for BRAF wild type, BRAF fusion, and BRAF V600E, respectively, on internal testing. On external testing, the pipeline yielded an AUC of 0.72 (95% CI 0.64, 0.86), 0.78 (95% CI 0.61, 0.89), and 0.72 (95% CI 0.64, 0.88) for BRAF wild type, BRAF fusion, and BRAF V600E, respectively. Conclusion Transfer learning and self-supervised cross-training improved classification performance and generalizability for noninvasive pediatric low-grade glioma mutational status prediction in a limited data scenario. Keywords Pediatrics, MRI, CNS, Brain/Brain Stem, Oncology, Feature Detection, Diagnosis, Supervised Learning, Transfer Learning, Convolutional Neural Network (CNN) Supplemental material is available for this article. © RSNA, 2024.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioma Limite: Child / Female / Humans / Male Idioma: En Revista: Radiol Artif Intell Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioma Limite: Child / Female / Humans / Male Idioma: En Revista: Radiol Artif Intell Ano de publicação: 2024 Tipo de documento: Article